JP2023516745A5 - - Google Patents
Info
- Publication number
- JP2023516745A5 JP2023516745A5 JP2022553181A JP2022553181A JP2023516745A5 JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5 JP 2022553181 A JP2022553181 A JP 2022553181A JP 2022553181 A JP2022553181 A JP 2022553181A JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- approximately
- pharmaceutical composition
- administered
- lsd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986541P | 2020-03-06 | 2020-03-06 | |
| US62/986,541 | 2020-03-06 | ||
| PCT/US2021/021101 WO2021178807A1 (en) | 2020-03-06 | 2021-03-05 | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516745A JP2023516745A (ja) | 2023-04-20 |
| JP2023516745A5 true JP2023516745A5 (cg-RX-API-DMAC7.html) | 2024-03-06 |
Family
ID=77614361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553181A Pending JP2023516745A (ja) | 2020-03-06 | 2021-03-05 | 小細胞肺癌および/または扁平上皮非小細胞肺癌の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230089536A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114398A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023516745A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220151637A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115484958A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021230575A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017637A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170456A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296564A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010912A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178807A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
| TW202329934A (zh) * | 2021-09-30 | 2023-08-01 | 日商大鵬藥品工業股份有限公司 | 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2019075327A1 (en) * | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| AU2018377852B2 (en) * | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| CA3143030A1 (en) * | 2019-06-13 | 2020-12-17 | Celgene Corporation | Methods of treating cancer by targeting cold tumors |
-
2021
- 2021-03-05 BR BR112022017637A patent/BR112022017637A2/pt not_active Application Discontinuation
- 2021-03-05 US US17/909,292 patent/US20230089536A1/en not_active Abandoned
- 2021-03-05 CN CN202180030907.0A patent/CN115484958A/zh active Pending
- 2021-03-05 MX MX2022010912A patent/MX2022010912A/es unknown
- 2021-03-05 KR KR1020227034176A patent/KR20220151637A/ko not_active Ceased
- 2021-03-05 WO PCT/US2021/021101 patent/WO2021178807A1/en not_active Ceased
- 2021-03-05 IL IL296564A patent/IL296564A/en unknown
- 2021-03-05 AU AU2021230575A patent/AU2021230575A1/en not_active Abandoned
- 2021-03-05 EP EP21714748.7A patent/EP4114398A1/en not_active Withdrawn
- 2021-03-05 JP JP2022553181A patent/JP2023516745A/ja active Pending
- 2021-03-05 CA CA3170456A patent/CA3170456A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Elslande et al. | Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection | |
| Petrone et al. | In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy | |
| Icenogle | COVID-19: infection or autoimmunity | |
| Farroni et al. | Kinetics of the B-and T-cell immune responses after 6 months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis | |
| JP2022536412A5 (cg-RX-API-DMAC7.html) | ||
| Woolsey et al. | Immune correlates of postexposure vaccine protection against Marburg virus | |
| Miyazaki et al. | Corneal endothelial cells activate innate and acquired arm of anti-viral responses after cytomegalovirus infection | |
| Luka et al. | Molecular characterization of peste des petits ruminants virus from the Karamoja region of Uganda (2007-2008) | |
| Aloisi et al. | MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis | |
| US20220257657A1 (en) | Manipulation and use of antigen-specific regulatory t cells | |
| An et al. | Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients | |
| CA3170456A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| JP2024539370A5 (cg-RX-API-DMAC7.html) | ||
| Zhou et al. | Comparing TCR beta chain variable gene profile skewness between children with tuberculosis and BCG-vaccinated children | |
| US20250147046A1 (en) | New method for identifying herv-derived epitopes | |
| Hagihara et al. | Clinical efficacy of imdevimab/casirivimab for persistent Omicron SARS-CoV-2 infection in patients with hematological malignancies | |
| Nogimori et al. | mRNA vaccine induces cytotoxic CD8+ T-cell cross-reactivity against SARS-CoV-2 Omicron variant and regulates COVID-19 severity | |
| Bellanger et al. | Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response | |
| US20260036592A1 (en) | DETECTION OF ANTI-VIRAL CDR3s IN CANCER | |
| Bartholomeus et al. | Transcriptomic profiling of different responder types in adults after a Priorix® vaccination | |
| Drennan et al. | Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response | |
| mM | Supplementary Figure | |
| ASSAID et al. | COVID-19: The immune responses and immunotherapy | |
| Smith | Impact of Advanced Age and Dietary Energy Balance on Mammary Tumor Progression and the Tumor Microenvironment | |
| Green et al. | Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder |